HK1202296A1 - Anti-adamts-5 antibody, derivatives and uses thereof - Google Patents

Anti-adamts-5 antibody, derivatives and uses thereof Download PDF

Info

Publication number
HK1202296A1
HK1202296A1 HK15102792.9A HK15102792A HK1202296A1 HK 1202296 A1 HK1202296 A1 HK 1202296A1 HK 15102792 A HK15102792 A HK 15102792A HK 1202296 A1 HK1202296 A1 HK 1202296A1
Authority
HK
Hong Kong
Prior art keywords
amino acid
seq
acid sequence
antibody
identity
Prior art date
Application number
HK15102792.9A
Other languages
English (en)
Chinese (zh)
Inventor
‧秋薩洛利
R‧秋萨洛利
‧維辛廷
M‧维辛廷
‧卡塞利
G‧卡塞利
‧羅瓦迪
L‧C‧罗瓦迪
Original Assignee
罗达制药生物技术有限责任公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 罗达制药生物技术有限责任公司 filed Critical 罗达制药生物技术有限责任公司
Publication of HK1202296A1 publication Critical patent/HK1202296A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/38—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6402—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals
    • C12N9/6405—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals not being snakes
    • C12N9/6416—Metalloendopeptidases (3.4.24)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK15102792.9A 2012-04-13 2013-04-12 Anti-adamts-5 antibody, derivatives and uses thereof HK1202296A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12164107.0 2012-04-13
EP12164107.0A EP2650310B1 (en) 2012-04-13 2012-04-13 Anti-ADAMTS-5 antibody, derivatives and uses thereof
PCT/EP2013/057649 WO2013153189A1 (en) 2012-04-13 2013-04-12 Anti-adamts-5 antibody, derivatives and uses thereof

Publications (1)

Publication Number Publication Date
HK1202296A1 true HK1202296A1 (en) 2015-09-25

Family

ID=48083198

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15102792.9A HK1202296A1 (en) 2012-04-13 2013-04-12 Anti-adamts-5 antibody, derivatives and uses thereof

Country Status (19)

Country Link
US (1) US9631029B2 (cs)
EP (2) EP2650310B1 (cs)
JP (1) JP2015518476A (cs)
KR (1) KR20150003278A (cs)
CN (1) CN104245737B (cs)
AR (1) AR090668A1 (cs)
AU (1) AU2013246880B2 (cs)
CA (1) CA2869031A1 (cs)
DK (1) DK2650310T3 (cs)
ES (1) ES2588484T3 (cs)
HK (1) HK1202296A1 (cs)
HU (1) HUE031089T2 (cs)
IN (1) IN2014MN01868A (cs)
MX (1) MX2014012295A (cs)
PL (1) PL2650310T3 (cs)
PT (1) PT2650310T (cs)
RU (1) RU2014145536A (cs)
TW (1) TWI579302B (cs)
WO (1) WO2013153189A1 (cs)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3501B1 (ar) 2014-12-22 2020-07-05 Servier Lab مشتقات 5-{(بيبرازين - 1-يل)-3-أوكسو - بروبيل}- إيميدازوليدين-2، 4 - دايون كمثبطات ل adamts لمعالجة هشاشة العظام)
RU2757314C2 (ru) 2016-01-22 2021-10-13 Мерк Шарп И Доум Корп. Антитела против фактора свертывания xi
GB201610055D0 (en) 2016-06-09 2016-07-27 Galapagos Nv And Laboratoires Servier Les Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders and osteoarthritis
GB201610056D0 (en) 2016-06-09 2016-07-27 Galapagos Nv And Laboratoires Servier Les Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders and osteoarthritis
JP7022081B2 (ja) 2016-06-14 2022-02-17 メルク・シャープ・アンド・ドーム・コーポレーション 抗凝固因子ｘｉ抗体
PL3630847T3 (pl) 2017-06-02 2025-02-03 Merck Patent Gmbh Immunoglobuliny wiążące adamts
IT201800003818A1 (it) * 2018-03-21 2019-09-21 Fond Per Listituto Oncologico Di Ricerca Ior Nuovi farmaci prosenescenza
FI129515B (en) 2020-11-06 2022-03-31 Salarusta Oy FOR USE IN THE PREVENTION AND / OR TREATMENT OF A DISEASE OR CONDITION RELATED TO THE DEGRADATION AND / OR DISTURBANCE OF THE DEGREE OF MONTOOSASE AND / OR INTEGRITY
CA3205021A1 (en) 2020-12-15 2022-06-23 Galapagos Nv Solid forms of (5s)-cyclopropyl-5-[3-[(3s)-4-(3,5-difluorophenyl)-3-methyl-piperazin-1-yl]-3-oxo-propyl]imidazolidine-2,4-dione
CN116256518B (zh) * 2023-02-24 2025-07-04 北京爱德诺生物科技有限公司 一种肿瘤诊断标志物及其诊断试剂盒和应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5484590A (en) * 1993-09-09 1996-01-16 La Jolla Cancer Research Foundation Expression of the developmental I antigen by a cloned human cDNA encoding a member of a β-1,6-N-acetylglucosaminyltransferase gene family
AU3622600A (en) 1999-03-08 2000-09-28 Neurocrine Biosciences, Inc. Metalloproteinases and methods of use therefor
US6391610B1 (en) * 1999-08-06 2002-05-21 The Cleveland Clinic Foundation Nucleic acids encoding zinc metalloproteases
EP1689716A1 (en) * 2003-12-04 2006-08-16 Wyeth Biaryl sulfonamides and methods for using same
CN102482700A (zh) 2009-07-02 2012-05-30 葛兰素集团有限公司 多肽和治疗方法

Also Published As

Publication number Publication date
AU2013246880A1 (en) 2014-10-16
EP2836516B1 (en) 2017-07-26
IN2014MN01868A (cs) 2015-07-03
TWI579302B (zh) 2017-04-21
WO2013153189A1 (en) 2013-10-17
US20150056210A1 (en) 2015-02-26
AU2013246880B2 (en) 2016-04-21
PL2650310T3 (pl) 2017-01-31
CN104245737A (zh) 2014-12-24
EP2650310B1 (en) 2016-06-08
CN104245737B (zh) 2017-04-05
EP2650310A1 (en) 2013-10-16
PT2650310T (pt) 2016-09-01
CA2869031A1 (en) 2013-10-17
HUE031089T2 (en) 2017-06-28
DK2650310T3 (en) 2016-09-12
RU2014145536A (ru) 2016-06-10
EP2836516A1 (en) 2015-02-18
AR090668A1 (es) 2014-11-26
US9631029B2 (en) 2017-04-25
MX2014012295A (es) 2014-11-10
JP2015518476A (ja) 2015-07-02
KR20150003278A (ko) 2015-01-08
ES2588484T3 (es) 2016-11-03
TW201402606A (zh) 2014-01-16

Similar Documents

Publication Publication Date Title
TWI579302B (zh) 抗－ａｄａｍｔｓ－５抗體、衍生物及其用途
CN102333542B (zh) Pcsk9拮抗剂
AU2010247464B2 (en) Humanized AXL antibodies
AU2007332855B2 (en) Monoclonal antibodies against ANGPTL3
JP6696899B2 (ja) プラスミノーゲン活性化因子阻害剤−１（ｐａｉ−１）に対する抗体及びその使用
US9114131B2 (en) Antibody targeting osteoclast-related protein Siglec-15
CN113366016B (zh) 抗人白细胞介素5(il-5)单克隆抗体及其应用
JP7112659B2 (ja) 抗ｐｃｓｋ９抗体およびその使用
HK1204477A1 (en) Single domain antibodies as inhibitors of pcsk9
JP2014511378A (ja) Ｐｃｓｋ９アンタゴニスト
EP3401336A1 (en) Pcsk9 antibody, antigen-binding fragment thereof, and medical uses thereof
WO2015056808A1 (en) Human antibody against aggrecanase-type adamts species for therapeutics of aggrecanase-related diseases
CN118047871A (zh) 一种靶向FRα的抗体或其抗原结合片段及其应用
KR20210158693A (ko) 항 ｐｃｓｋ９ 항체 및 이의 용도
WO2001051507A1 (fr) Nouveau peptide et procede de criblage utilisant ledit peptide